# Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours

Study · id `cardio:ct-nct07912970` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07912970](<https://clinicaltrials.gov/study/NCT07912970>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07912970

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1266 participants.

## Technical summary

Registry record NCT07912970. Randomized; single masking; primary purpose treatment. Start 2027-04-01 (anticipated); primary completion 2029-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1266 participants (planned count; ClinicalTrials.gov record NCT07912970, source copy `cardio:ctgov-nct07912970-2026-11-03`, retrieved 2026-11-18)
- Planned start: 2027-04-01 (anticipated) (ClinicalTrials.gov record NCT07912970, source copy `cardio:ctgov-nct07912970-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2029-12-01 (anticipated) (ClinicalTrials.gov record NCT07912970, source copy `cardio:ctgov-nct07912970-2026-11-03`, retrieved 2026-11-18)
- Completion: 2030-03-01 (anticipated) (ClinicalTrials.gov record NCT07912970, source copy `cardio:ctgov-nct07912970-2026-11-03`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07912970, source copy `cardio:ctgov-nct07912970-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07912970-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours
- Acronym: Union-transfer
- Condition: Acute Ischemic Stroke
- Condition: Large Vessel Occlusion
- Intervention (Drug): Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
- Lead sponsor: Fujian Medical University Union Hospital
- Lead sponsor class: OTHER
- Collaborator: Zhangzhou Affiliated Hospital of Fujian Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Tenecteplase (`cardio:tenecteplase`)
- Registry intervention is a member of this class by a sourced record link: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)
- Registry lists this organization as the lead sponsor: Fujian Medical University Union Hospital (`cardio:org-fujian-medical-university-union-hospital`)

## Provenance

Content hash: 76db7395a73bdc2874cb43b2695687141dbdb5ff0f555eac981f2715eb49f8b3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
